|
Re: Zenith website undergoing changes
|
2
|
Zenith Epigenetics
|
Mar 03, 2016 02:25PM
|
|
Re: DSMB
|
2
|
Resverlogix Corp.
|
Feb 21, 2019 08:33PM
|
|
Re: Latest MD&A and Financials up on SEDAR
|
2
|
BIOASIS TECHNOLOGIES INC
|
Jan 29, 2018 11:50PM
|
|
Re: AACR April 24-29, 2020 for some Zenith Clinical Trial Results?
|
2
|
Zenith Epigenetics
|
Apr 19, 2020 01:41PM
|
|
Re: You're right 10bagr, you didn't sway me....
|
2
|
Resverlogix Corp.
|
Feb 01, 2019 03:30PM
|
|
Re: EASD 2019 Sept 16-20, 2019
|
2
|
Resverlogix Corp.
|
Jul 19, 2019 10:26AM
|
|
Re: Zenith Announces Initiation of Phase 1b ZEN-3694 Trial
|
2
|
Zenith Epigenetics
|
Dec 14, 2016 05:46PM
|
|
Re: AACR April 24-29, 2020 for some Zenith Clinical Trial Results?
|
2
|
Zenith Epigenetics
|
Apr 19, 2020 01:55PM
|
|
Re: New blog post
|
2
|
Resverlogix Corp.
|
May 28, 2015 02:02PM
|
|
Re: Share offering a win/win for shareholders?
|
2
|
Resverlogix Corp.
|
May 24, 2019 12:17PM
|
|
Very close to Final Draft of Checklist for Management - Included info from MD&A
|
2
|
Resverlogix Corp.
|
Jul 28, 2016 12:08PM
|
|
Re: Sub-study Forest Plot
|
2
|
Resverlogix Corp.
|
Nov 16, 2019 03:11PM
|
|
Re: American Diabetes Association 2017 Abstract
|
2
|
Resverlogix Corp.
|
Jun 03, 2017 10:07PM
|
|
Re: ...somebody’s having fun...
|
2
|
Resverlogix Corp.
|
Feb 21, 2019 09:39PM
|
|
Re: Showcase Presentations
|
2
|
Resverlogix Corp.
|
Jan 16, 2017 06:11PM
|
|
Re: Chronic Kidney Disease and BET inhibition, event coming up
|
2
|
Resverlogix Corp.
|
Mar 29, 2017 09:16AM
|
|
Re: What If - Uses of Apabetalone
|
2
|
Resverlogix Corp.
|
Aug 12, 2018 05:34PM
|
|
Re: HDL function is associated with atherosclerotic burden and cardiovascular outcomes in T2D
|
2
|
Resverlogix Corp.
|
Oct 16, 2018 06:45PM
|
|
Re: BioPub Bioasis Webcast
|
2
|
BIOASIS TECHNOLOGIES INC
|
Nov 02, 2019 11:43AM
|
|
Re: Vaccinex
|
2
|
BIOASIS TECHNOLOGIES INC
|
Sep 03, 2018 09:13AM
|
